// App-Quantinova.ai

OP143 : Regular drug-eluting stent versus dedicated bifurcation sirolimus-eluting stent in the coronary bifurcation treatment: the randomised, multicentre, open-label, controlled POLBOS II trial

Researchers

Presenter

  • Gil R

Principal Investigators

  • Bil J

  • Dobrin V

  • Kern A

  • Inigo Garcia L

  • Formussewicz R

  • Dobrzycki S

Medical Centers

  • Alexandrovska University Hospital, Sofia, CA

  • Central Clinical Hospital of the Ministry of Interior, Warsaw, Poland

  • Department of Endocrinology and Diabetes with Internal Medicine, Medical University in Bialystok, Bialystok, Poland

  • Costa del Sol Hospital, Marbella, Spain

  • Faculty of Medical Sciences University of Varmia and Masuria, Olsztyn, Poland

  • th Clinical Military Hospital, Bydgoszcz, Poland

Locations

  • Poland

  • Spain

  • Bulgaria

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Stable coronary artery disease

  • Peripheral artery disease

  • Coronary Artery Disease

  • Myocardial infarction

  • Venous thrombosis

  • Diabetes

Biomarkers

  • Tumor protein p63

Drug/Treatment

  • sirolimus

  • Everolimus

  • Paclitaxel

  • Rapacan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved